Termination for Safety. 16.2.6.1. SGEN may terminate this Agreement with respect to a Collaboration Product (other than a CoDev Product) immediately upon written notice to PIRS, that such Collaboration Product demonstrates a Safety Issue in humans. 16.2.6.2. Subject to consultation with the JSC (which shall be expedited by the Parties), PIRS or SGEN may terminate this Agreement with respect to a CoDev Product immediately upon written notice to the other Party, if such CoDev Product demonstrates a Safety Issue in humans. 16.2.6.3. For purposes of this Section 16.2.6, “Safety Issue” means instances, in which either the FDA or the EMA require that the Development, Manufacture, or Commercialization of a CoDev Product be stopped.
Appears in 2 contracts
Sources: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.), License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Termination for Safety. 16.2.6.1. 16.2.6.1 SGEN may terminate this Agreement with respect to a Collaboration Product (other than a CoDev Product) immediately upon written notice to PIRS, that such Collaboration Product demonstrates a Safety Issue in humans.
16.2.6.2. 16.2.6.2 Subject to consultation with the JSC (which shall be expedited by the Parties), PIRS or SGEN may terminate this Agreement with respect to a CoDev Product immediately upon written notice to the other Party, if such CoDev ▇▇▇▇▇ Product demonstrates a Safety Issue in humans.
16.2.6.3. 16.2.6.3 For purposes of this Section 16.2.6, “Safety Issue” means instances, in which either the FDA or the EMA require that the Development, Manufacture, or Commercialization of a CoDev Product be stopped.
Appears in 1 contract
Sources: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)